Related Experiment Video
Updated: Oct 8, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Scottish Airways Research Network (SARN) Delphi Consensus on pre-biologic assessment, clinical remission and
Sunny Jabbal1, Rekha Chaudhuri2, Andrew Smith3
1Victoria Kirkcaldy Hospital, Kirkcaldy, Scotland, United Kingdom.
Introduction:
Scotland's severe asthma multidisciplinary teams and prescribing recommendations may contribute to variation in biologic decisions. We sought expert consensus on pre-biologic assessment, clinical remission and post-remission management through the Scottish Airways Research Network (SARN).
Methods:
A scientific committee developed 28 statements across these three domains. Thirty specialists from 15 centres rated statements using a five-point Likert scale. Consensus was predefined as >75% agreeing or strongly agreeing. Statements requiring revision were considered in Round 2.
Results:
Twenty-four panellists completed Round 1 (80% response), achieving consensus on 15/28 statements (53.6%); 23 completed Round 2 (76.7% response), achieving consensus on 10/13 revised statements (76.9%). Pre-biologic assessment should include treatment optimisation, comprehensive phenotyping, type 2 biomarkers, exacerbation history, comorbidities and patient characteristics. Clinical remission should generally be assessed after at least 12 months and comprise freedom from maintenance oral corticosteroids, absent or minimal symptoms, no severe exacerbations, stable lung function, normalised asthma-related quality of life, and patient-healthcare professional agreement. Improved lung function, reduced airway inflammation and treatment burden, and normalised airway hyperresponsiveness were desirable but not mandatory. No consensus was reached on a specific Asthma Control Questionnaire threshold for remission or restricting biologic access among current smokers not participating in smoking cessation. Dosing-interval extension or discontinuation should not be routine but may be considered for selected patients with sustained remission under specialist supervision, shared decision-making, close monitoring and a rapid restart plan.
Conclusion:
This Scottish Delphi study provides a pragmatic framework to support equitable, consistent decisions on pre-biologic assessment, remission and treatment de-escalation.
Related Concept Videos
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-IV: Nursing Management
First, in...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Respiratory Syncytial Virus Disease
Asthma III: Clinical Manifestations
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: